Muhammad Kashif Riaz , MD

Medical Degree: University of Health Sciences Lahore, Pakistan, 2005 (Medicine)

Internship: Shaukat Khanum Hospital Lahore, Pakistan, 2010

Residency: The Jewish Hospital Cincinnati, Ohio, 2014

Fellowship: University of Cincinnati Cincinnati, Ohio, 2017

American Board of Internal Medicine (Hematology) (Certification Date: 10-31-2017 )

American Board of Internal Medicine (Certification Date: 08-20-2014 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-01-2017 )

Hematology and Oncology

Lung Cancer

Oncology

Thyroid Cancer

Bladder Cancer

Kidney Cancer

Mesothelioma

Prostate Cancer

Renal Cell Carcinoma

Testicular Cancer

Thymoma

Ureter Cancer

Urethral Cancer

Urothelial Cancer

Hematology

Internal Medicine

Medical Oncology

Hematology Oncology

2016 -2017 Chief Fellow, University of Cincinnati,, Cincinnati, OH

2017 - Assistant Professor, University of Cincinnati,, Cincinnati, OH

2019 - Assistant Professor (Adjunct), Veterans Affair Medical Center, Cincinnati, OH

2019 - Associate Program Director, Fellowship, University of Cincinnati,, Cincinnati, OH

2018 -2020 Head & Neck Cancer Clinical Trials Leader, University of Cincinnati, Barrett Cancer Center, Cincinnati, OH

2019 - Associate Program Director, Hematology/Oncology Fellowship, University of Cincinnati,, Cincinnati, OH

2015 -2017 Hospitalist Physician, The Jewish Hospital, Cincinnati, OH

2017 - Staff Physician, University of Cincinnati,, Cincinnati, OH

2019 - Adjunct Physician, Veterans Affairs Medical Center, Cincinnati, OH

Grant: #CA001-050 Investigators:Riaz, Muhammad 09-01-2021 -08-31-2024 Bristol-Myers Squibb Co. A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Role:PI 532748.15 Hold Level:Industry

Grant: #PrE0506 Investigators:Riaz, Muhammad 10-01-2021 -10-01-2024 PrECOG, LLC DuRvalumab MEDI4736 with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial (DREAM3R) Role:PI 74001.00 Hold Level:Industry

Investigators:Riaz, Muhammad 11-01-2021 -11-01-2024 TopAlliance Biosciences Inc. A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination Role:PI 1165367.76 Hold Level:Industry

Grant: #GMO221215; PO No.0000002543; Prime Grant No. G-18-100 Investigators:Riaz, Muhammad 01-01-2022 -02-15-2023 University of Texas Southwestern Medical Center A Phase 2 Single-Center Pharmacodynamic Study of TVB-2640 in KRAS Mutant Non-Small Cell Lung Carcinomas Role:PI 11000.00 Hold Level:Higher Education

Investigators:Riaz, Muhammad -02-15-2022 University of Texas Southwestern Medical Center A Phase 2 Single-Center Pharmacodynamic Study of TVB-2640 in KRAS Mutant Non-Small Cell Lung Carcinomas Role:PI 0.00 Hold Level:Higher Education

Peer Reviewed Publications

Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. (01-15-2020. ) Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in.Cancer, , 126 (2 ) ,354-362 More Information

Haque S.;Karivedu V.;Riaz M.K.;Choi D.;Roof L.;Hassan S.Z.;Zhu Z.;Jandarov R.;Takiar V.;Tang A.;Wise-Draper T. (01-01-2019. ) High-risk pathological features at the time of salvage surgery predict poor survival after definitiv.Oral Oncology, , 88 ,9-15 More Information

Eldessouki I.;Gaber O.;Riaz M.K.;Wang J.;Karim N.A. (09-01-2018. ) Clinical presentation and treatment options for clear cell lung cancer: University of Cincinnati a c.Asian Pacific Journal of Cancer Prevention, , 19 (9 ) ,2373-2376 More Information

Riaz M.K.;Bal S.;Wise-Draper T. (09-01-2016. ) The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic canc.Journal of Surgical Oncology, , 114 (3 ) ,323-328 More Information

2014: Diplomat American Board of Internal Medicine

2017: Diplomat American Board of Hematology

2017: Diplomat American Board of Medical Oncology

2011: American College of Physicians (ACP)

2013: American Federation for Medical Research (AFMR)

2014: American Society of Hematology (ASH)

2014: American Society of Clinical Oncology (ASCO)

2015: International Association for the Study of Lung Cancer (IASLC)

Dr. Riaz CV

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2119
Fax: 513-558-2124
muhammad.riaz2@uc.edu